Online citations, reference lists, and bibliographies.

Chapter 46 – Uncommon Thoracic Tumors

J. Zeng, R. Rengan, C. Thomas
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1371/journal.pone.0066047
A Gene Signature to Determine Metastatic Behavior in Thymomas
Yesim Gökmen-Polar (2013)
10.1002/bjs.1800590708
The role of radiotherapy in the management of malignant thymoma
C. R. Penn (1972)
10.1016/0360-3016(91)90054-8
Deterioration in lung function following hemithorax irradiation for pleural mesothelioma.
P. Maasilta (1991)
10.1016/0003-4975(91)90478-9
[Thymoma: results of 241 operated cases].
G. Maggi (1990)
10.1016/S0003-4975(98)01063-7
Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients.
I. Fukai (1999)
10.1097/JTO.0b013e3181e8f345
The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis
A. Fernandes (2010)
10.1053/HUPA.2000.19294
Pulmonary atypical carcinoid: predictors of survival in 106 cases.
M. Beasley (2000)
10.1378/CHEST.112.4_SUPPLEMENT.272S
Multimodality therapy for malignant pleural mesothelioma.
D. Sugarbaker (1997)
10.1016/S0360-3016(02)03796-3
Outcomes and patterns of failure in bronchial carcinoid tumors.
B. Kaplan (2003)
10.1016/j.athoracsur.2013.04.057
Importance of lymph node dissection in thymic carcinoma.
I. Park (2013)
10.1093/ejcts/ezt305
The oncological feasibility and limitations of video-assisted thoracoscopic thymectomy for early-stage thymomas.
T. Kimura (2013)
10.1016/0360-3016(82)90379-0
Radiation therapy in the management of patients with mesothelioma.
W. Gordon (1980)
10.3816/CLC.2009.n.033
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
Brad E Wilcox (2009)
10.1016/S0003-4975(98)00083-6
Operative risk and prognostic factors of typical bronchial carcinoid tumors.
X. Ducrocq (1998)
10.1080/02841860410018575
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) Part I—General Overview
K. Öberg (2004)
10.1016/J.IJROBP.2007.02.047
Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
A. Allen (2007)
10.1016/j.athoracsur.2010.01.038
Assessment of robotic thymectomy using the Myasthenia Gravis Foundation of America Guidelines.
S. Goldstein (2010)
10.1002/cncr.22404
Topoisomerase 2α plays a pivotal role in the tumor biology of stage IV thymic neoplasia
J. Liu (2007)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1093/ANNONC/10.SUPPL_2.S23
Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
E. Krenning (1999)
10.7326/0003-4819-117-3-209
The Cushing syndrome induced by bronchial carcinoid tumors.
A. Limper (1992)
10.1016/0360-3016(91)90061-8
The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors.
K. Schupak (1991)
10.1158/1078-0432.CCR-09-0644
Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas
N. Girard (2009)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1093/ajcp/104.4.375
p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study.
H. Tateyama (1995)
10.1016/0003-4975(92)91139-Z
Bronchial carcinoid tumors: a retrospective analysis of 126 patients.
D. Harpole (1992)
10.1016/S0169-5002(00)00119-7
Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases.
A. Carretta (2000)
10.1016/S0003-4975(03)00555-1
Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan.
K. Kondo (2003)
10.1097/00000478-199001000-00003
Thymic Carcinomas: Histopathological Varieties and Immunohistochemical Study
T. Kuo (1990)
10.1007/BF00737071
Thymoma and thymic carcinoma
M. Marino (1985)
10.1023/A:1012569909313
Experience in treatment of metastatic pulmonary carcinoid tumors.
D. Granberg (2001)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1097/00000658-199807000-00015
Thymic carcinoids in multiple endocrine neoplasia type 1.
B. Teh (1998)
10.1097/01.COC.0000020584.56294.72
Atypical Thymic Carcinoid and Malignant Somatostatinoma in Type I Multiple Endocrine Neoplasia Syndrome: Case Report
F. C. Lin (2003)
10.1093/infdis/170.1.7
Thymic carcinoma with a defective Epstein-Barr virus encoding the BZLF1 trans-activator.
D. Patton (1994)
10.1016/J.IJROBP.2003.11.021
Thymic carcinoma: state of the art review.
T. Eng (2004)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1093/AJCP/111.2.235
Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma.
H. Tateyama (1999)
10.1016/S0046-8177(96)90140-9
Cell kinetic study of thymic epithelial tumors using PCNA (PC10) and Ki-67 (MIB-1) antibodies.
W. Yang (1996)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1126/science.1200609
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Y. Jiao (2011)
10.1097/JTO.0b013e3181f21114
Targeted Therapy for Advanced Thymic Tumors
A. Rajan (2010)
10.1016/0360-3016(81)90481-8
Computerized tomography scanning and the planning of high-dose radiotherapy for pleural mesothelioma: a report of five patients.
P. Bricout (1981)
10.1016/j.jtcvs.2009.02.046
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1097/JTO.0b013e318292c41e
A Prospective Phase II Trial of Induction Chemotherapy with Docetaxel/Cisplatin for Masaoka Stage III/IV thymic Epithelial Tumors
Silvia J. H. Park (2013)
10.1016/S0039-6109(16)41736-6
The APUD cell system and its neoplasms: observations on the significance and limitations of the concept.
V. Gould (1979)
10.1056/NEJM198505163122006
Association of Epstein-Barr virus with thymic carcinoma.
S. Leyvraz (1985)
10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4
Carcinoid Tumors An analysis of 2837 cases
J. Godwin (1975)
10.1002/1097-0142(19860801)58:3<765::AID-CNCR2820580326>3.0.CO;2-S
Thymomas: A review of 169 cases, with particular reference to results of surgical treatment
G. Maggi (1986)
10.1007/s12032-013-0479-x
Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute
B. Han (2013)
10.2214/AJR.176.2.1760433
Malignant thymic epithelial tumors: CT-pathologic correlation.
K. Jung (2001)
10.1016/J.HLC.2006.08.010
Superior vena cava obstruction by tumour thrombus in invasive thymoma: diagnosis and surgical management.
I. Konstantinov (2007)
10.1016/S0046-8177(96)90289-0
Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness.
F. Chen (1996)
10.1053/j.seminoncol.2012.11.003
Systemic therapeutic options for carcinoid.
M. Pavel (2013)
10.1097/00005382-199601110-00007
Thymic Carcinoma: Case Reports and Review
P. Quagliano (1996)
10.1186/1471-2482-2-3
Clinical and immunohistochemical study of eight cases with thymic carcinoma
M. Tomita (2002)
10.1634/THEONCOLOGIST.6-3-239
Thymoma: update for the new millennium.
S. B. Johnson (2001)
10.1097/00005792-200103000-00005
Infections in Patients with Immunodeficiency with Thymoma (Good Syndrome): Report of 5 Cases and Review of the Literature
P. Tarr (2001)
10.1378/chest.93.2.370
Atypical carcinoid of the lung. A distinct clinicopathologic entity.
T. Grote (1988)
10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R
Follow‐up study of thymomas with special reference to their clinical stages
A. Masaoka (1981)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.1002/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F
Thymic carcinoma. A clinicopathologic study of 60 cases
S. Suster (1991)
10.1002/cncr.10136
Diagnostic dilemmas in pulmonary cytology
J. Crapanzano (2001)
10.1111/j.1440-1827.1994.tb02600.x
Thymic carcinoma: proposal for pathological TNM and staging.
R. Tsuchiya (1994)
10.3960/JSLRT.53.9
The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.
A. Hayashi (2013)
10.1016/S0360-3016(01)02589-5
Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation.
A. Della Volpe (2002)
10.1016/J.LUNGCAN.2005.03.006
Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging.
H. Steinert (2005)
10.1016/0277-5379(84)90036-1
Invasive carcinoma of the thymus. A multicenter retrospective review of 56 cases.
R. Arriagada (1984)
10.1002/jso.2930500317
Thyroid and thymic malignancy following childhood irradiation.
M. O. Jensen (1992)
10.1016/J.JTCVS.2007.07.049
Feasibility of multimodality therapy including extended resections in stage IVA thymoma.
J. Huang (2007)
10.1177/021849230301100411
Predictors of Outcome for Myasthenia Gravis after Thymectomy
Y. Elmedany (2003)
10.1016/0026-0495(85)90009-5
Increased dopamine production in patients with carcinoid tumors.
J. Feldman (1985)
10.1002/1097-0142(19931001)72:7<2273::AID-CNCR2820720735>3.0.CO;2-U
Disseminated mediastinal carcinoma with chromosomal translocation (15;19). A distinctive clinicopathologic syndrome
A. Lee (1993)
10.1097/JTO.0b013e3181ed0489
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
10.7326/0003-4819-129-2-199807150-00006
A Multidisciplinary Approach to Therapy for Unresectable Malignant Thymoma
D. Shin (1998)
10.1016/0002-9343(86)90583-8
Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.
J. Feldman (1986)
10.1038/sj.bjc.6605740
Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience
P. Stroebel (2010)
10.1016/J.IJROBP.2005.03.041
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
V. Gupta (2005)
10.1097/00000658-199608000-00016
Is postoperative radiotherapy for thymoma effective?
M. Haniuda (1996)
10.1097/00000658-199709000-00012
Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis.
G. Bulkley (1997)
10.1007/BF02939369
Substance p secretion by carcinoid tumours
P. Skrabanek (1978)
10.1016/j.jtcvs.2013.08.061
Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial.
R. Korst (2014)
10.1097/JTO.0b013e31827740f0
Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma
D. Gomez (2013)
10.3109/0284186X.2013.769063
Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer
R. Colaco (2013)
10.1016/J.ATHORACSUR.2005.05.042
Does an anecdote substantiate dogma?
F. Detterbeck (2006)
10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2
An analysis of 8305 cases of carcinoid tumors
I. Modlin (1997)
10.1016/0167-8140(92)90227-L
Aggressive treatment of intrathoracic recurrences of thymoma.
A. Urgesi (1992)
10.1002/1097-0142(19871215)60:12<2891::AID-CNCR2820601207>3.0.CO;2-6
A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A southwest oncology group study
R. Bukowski (1987)
10.1002/1097-0142(197408)34:2<389::AID-CNCR2820340224>3.0.CO;2-Z
Thymomas: Clinicopathologic features, therapy, and prognosis
M. Batata (1974)
10.1097/JTO.0b013e3181f1f63f
The Autoimmune Regulator AIRE in Thymoma Biology: Autoimmunity and Beyond
A. Marx (2010)
10.1378/chest.112.2.511
Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum.
D. Strollo (1997)
10.1016/S0022-5223(96)70409-9
Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases.
V. de Montpréville (1996)
10.1016/j.athoracsur.2010.01.026
Prognostic indicators after surgery for thymoma.
I. Okereke (2010)
10.1097/RTI.0b013e31828609a0
Advances in Thymoma Imaging
E. Marom (2013)
10.1179/oeh.2004.10.1.26
Malignant Pleural Mesothelioma—An Update
D. Stewart (2004)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1016/J.ATHORACSUR.2003.08.004
Seeding of stage I thymoma into the chest wall 12 years after needle biopsy.
Hassan Kattach (2005)
10.1097/00000478-199508000-00007
Long‐term Survival of Thymoma Patients by Histologic Pattern and Proliferative Activity
A. Pich (1995)
10.1016/S1052-3359(02)00038-8
Surgical treatment of other bronchial tumors.
W. Scott (2003)
10.1056/NEJMoa1009290
Everolimus for advanced pancreatic neuroendocrine tumors.
J. Yao (2011)
10.1001/ARCHNEUR.57.4.527
Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
Å. Mygland (2000)
10.2214/AJR.170.5.9574618
Evaluation of primary pulmonary carcinoid tumors using FDG PET.
J. Erasmus (1998)
10.1002/(SICI)1096-9098(199610)63:2<99::AID-JSO6>3.0.CO;2-J
Carcinoid tumors of the lung: immuno- and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically.
K. Kayser (1996)
10.1016/S0165-4608(03)00098-0
Deletion (6)(p22p25) is a recurrent anomaly of thymoma: report of a second case and review of the literature.
C. Herens (2003)
10.1016/S0003-4975(02)03547-6
Primary neuroendocrine tumors of the thymus.
R. Chaer (2002)
10.1097/00000478-198210000-00003
Primary thymic carcinomas
M. Wick (1982)
10.1007/s00277-003-0635-z
B-cell lymphopenia and hypogammaglobulinemia in thymoma patients
L. Montella (2003)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1016/1010-7940(93)90033-8
Clinical features and therapy of "typical" and "atypical" bronchial carcinoid tumors (grade 1 and grade 2 neuroendocrine carcinoma).
F. Smolle-Jüttner (1993)
10.1245/ASO.2003.09.019
Update in Pulmonary Carcinoid Tumors: A Review Article
R. Hage (2003)
10.1136/jcp.48.5.447
Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen.
N. Gilhus (1995)
10.18632/ONCOTARGET.1015
Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses
J. Wheler (2013)
10.1016/J.ATHORACSUR.2004.05.007
Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
R. Bueno (2004)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
10.1210/JCEM.86.2.7194
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
G. Kaltsas (2001)
10.1007/BF01728801
Malignant mesothelioma of the pleura
A. Calavrezos (2005)
10.1200/JCO.2007.15.9020
Activity of sunitinib in patients with advanced neuroendocrine tumors.
Matthew H. Kulke (2008)
10.1002/1097-0142(196509)18:9<1131::AID-CNCR2820180914>3.0.CO;2-F
Pathology and clinical behavior of thymomas. A survey of 51 cases
M. Legg (1965)
10.1002/(SICI)1097-0142(19990201)85:3<600::AID-CNCR10>3.0.CO;2-W
Genetic changes in the spectrum of neuroendocrine lung tumors
N. Onuki (1999)
10.1378/chest.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1016/S1010-7940(99)00052-4
Thymectomy for myasthenia gravis: a 27-year experience.
F. Venuta (1999)
10.1016/J.HUMPATH.2003.07.013
Expression of matrix metalloproteinases 2 and 7 in tumor cells correlates with the World Health Organization classification subtype and clinical stage of thymic epithelial tumors.
E. Takahashi (2003)
10.1097/00000478-200106000-00015
Thyroid Transcription Factor-1 Distinguishes Metastatic Pulmonary From Well-Differentiated Neuroendocrine Tumors of Other Sites
A. Oliveira (2001)
10.1148/RG.261055057
Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings.
S. Chong (2006)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.1016/J.LUNGCAN.2003.12.010
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
E. Kim (2004)
10.1056/NEJM197801192980305
Myasthenia Gravis.
D. Drachman (1978)
10.1007/s00428-013-1371-y
Thymic carcinomas: clinicopathologic study of 37 cases from a single institution
V. Thomas de Montpréville (2013)
10.1016/0277-5379(89)90266-6
Radiation sensitivity of human lung cancer cell lines.
J. Carmichael (1989)
10.1093/JJCO/HYL028
Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
E. Suzuki (2006)
10.1007/S11864-000-0047-4
Malignant pleural mesothelioma
H. Kindler (2000)
10.1002/1097-0142(19940715)74:2<606::AID-CNCR2820740212>3.0.CO;2-T
Thymoma: Histologic subclassification is an independent prognostic factor
L. Quintanilla-Martinez (1994)
10.1200/JCO.2009.22.8585
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
D. Bushnell (2010)
10.1016/0167-8140(88)90043-6
Magnetic resonance imaging and high-resolution computed tomography in tumors of the lung and the mediastinum.
F. Casamassima (1988)
10.1016/0003-4975(91)90848-K
Primary cysts and tumors of the mediastinum.
A. Cohen (1991)
10.1016/0360-3016(90)90056-P
Radiation therapy of invasive thymoma.
A. Arakawa (1990)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/0360-3016(84)90050-6
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
B. Hilaris (1984)
10.1016/j.lungcan.2013.08.003
Role of combined 18F-FDG-PET/CT for predicting the WHO malignancy grade of thymic epithelial tumors: a multicenter analysis.
F. Lococo (2013)
10.1016/J.LUNGCAN.2003.11.016
Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.
L. Wirth (2004)
10.1136/thx.22.3.193
Tumours of the thymus. A review of 88 operation cases.
Sellors Th (1967)
10.1016/S0003-4975(00)01369-2
Original articlePrognostic factors in neuroendocrine lung tumors: a Spanish multicenter study
M. García-Yuste (2000)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1002/cncr.10665
New WHO histologic classification predicts prognosis of thymic epithelial tumors
G. Chen (2002)
10.1097/00000478-199106000-00003
Neuroendocrine Tumors of the Lung With Proposed Criteria for Large‐Cell Neuroendocrine Carcinoma: An Ultrastructural, Immunohistochemical, and Flow Cytometric Study of 35 Cases
W. Travis (1991)
10.1200/JCO.2005.04.1202
Neuroendocrine neoplasms of the lung: a prognostic spectrum.
H. Asamura (2006)
10.1016/S0003-4975(97)00629-2
Multimodality treatment of thymoma: a prospective study.
F. Venuta (1997)
10.1016/S0003-4975(10)62059-0
Primary cysts and neoplasms of the mediastinum: recent changes in clinical presentation, methods of diagnosis, management, and results.
R. Davis (1987)
10.1056/NEJM200406173502523
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
P. Stroebel (2004)
10.1093/ejcts/ezt224
Resection of thymomas with use of the new minimally-invasive technique of extended thymectomy performed through the subxiphoid-right video-thoracoscopic approach with double elevation of the sternum.
M. Zieliński (2013)
10.1097/JTO.0b013e31818b06e3
The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
W. Travis (2008)
10.1093/ejcts/ezs527
The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours.
K. Fukumoto (2012)
10.1016/S1010-7940(02)00085-4
Sleeve lobectomy for non-small cell lung cancer and carcinoids: results in 160 cases.
A. Terzi (2002)
10.1038/sj.bjc.6605731
A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
H. Kunitoh (2010)
10.1016/S0002-9440(10)64426-4
Chromosome 6 suffers frequent and multiple aberrations in thymoma.
M. Inoue (2002)
10.1148/RADIOLOGY.211.3.R99JN03657
Malignant pleural mesothelioma: US-guided histologic core-needle biopsy.
A. Heilo (1999)
10.1002/cncr.23034
Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma
L. Greillier (2007)
10.1038/sj.onc.1201034
Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors
A. Abdollahi (1997)
10.1016/S0003-4975(10)63498-4
Tumors of the thymus and thymic region: I. Clinicopathological studies on thymomas.
N. Bergh (1978)
10.1016/j.jtcvs.2009.10.024
Type B thymoma: is prognosis predicted only by World Health Organization classification?
H. Kim (2010)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1200/JCO.2007.13.6374
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
J. Yao (2008)
10.1067/MSY.2001.110426
Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years.
H. Nave (2001)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1093/ejcts/ezs529
Clinicopathological features of thymic carcinomas and the impact of histopathological agreement on prognostical studies.
A. Roden (2013)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
10.1007/s005950170021
Elevated Serum Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Levels in Patients with Thymic Epithelial Neoplasms
H. Sasaki (2001)
10.1016/S1010-7940(01)00666-2
The multimodality treatment of thymic carcinoma.
M. Lucchi (2001)
10.1007/BF02012403
Paediatric thymoma: Unusual occurrence in two siblings
W. Lam (2005)
10.1016/S0360-3016(01)02656-6
Postoperative radiotherapy in thymic carcinoma: treatment results and prognostic factors.
H. C. Hsu (2002)
10.1002/cncr.11105
A 5‐decade analysis of 13,715 carcinoid tumors
I. Modlin (2003)
10.1002/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H
Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma
P. Macchiarini (1991)
10.1002/cncr.23542
Bronchopulmonary neuroendocrine tumors
B. Gustafsson (2008)
10.1016/S0003-4975(00)01369-2
Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR).
M. García-Yuste (2000)
10.1016/0140-6736(92)91235-Z
Ondansetron in carcinoid syndrome
A. J. Platt (1992)
10.1002/ana.1017
Mature, long‐lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis
C. Buckley (2001)
10.1186/1477-7819-11-157
Video-assisted thoracoscopic surgery versus robotic-assisted thoracoscopic surgery in the surgical treatment of Masaoka stage I thymoma
B. Ye (2013)
10.1200/JCO.2007.15.4377
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
J. Yao (2008)
10.1007/BF01608334
Thymic epithelial tumours: Evaluation of malignant grade by quantification of proliferating cell nuclear antigen and nucleolar organizer regions
H. Tateyama (2005)
10.1148/RADIOL.2232011131
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.
E. Marom (2002)
10.1016/S0003-4975(10)64915-6
Carcinoid tumors of the lung.
N. Okike (1976)
10.1378/chest.111.1.106
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
10.3109/02841869009090025
The role of preoperative radiotherapy for invasive thymoma.
K. Ohara (1990)
10.1016/S0169-5002(98)00075-0
Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy.
M. Musi (1998)
10.1172/JCI117090
Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
A. Kubota (1994)
10.1016/J.ATHORACSUR.2005.11.067
Clinical value of the WHO classification system of thymoma.
F. Detterbeck (2006)
10.1177/021849230201000213
Thymoma Associated with Pure Red-Cell Aplasia: Clinical Features and Prognosis
T. Murakawa (2002)
10.1002/jso.2930540311
Treatment of invasive thymoma with pleural dissemination.
Y. Ichinose (1993)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0039-6060(97)90090-8
Bronchial carcinoid--twenty years' experience defines a selective surgical approach.
T. Chughtai (1997)
10.1016/0360-3016(87)90173-8
Technique for external beam treatment for mesothelioma.
G. Kutcher (1987)
10.1038/sj.bjc.6602245
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression
A. Couvelard (2005)
10.1016/S1010-7940(01)00634-0
Extended thymectomy in myasthenia gravis: a team-work of neurologist, thoracic surgeon and anaesthesist may improve the outcome.
A. Mussi (2001)
10.1200/JCO.2003.05.123
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
K. Fizazi (2003)
10.1016/1010-7940(90)90140-U
Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour. Report on 227 cases.
G. Stamatis (1990)
10.1016/J.IJROBP.2007.07.2370
Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy.
J. Krayenbuehl (2007)
10.1016/j.ijrobp.2009.02.016
Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease.
Jeffrey A. Forquer (2010)
10.4161/cbt.10.5.12616
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma
K. Du (2010)
10.1016/0165-5728(94)00134-A
Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells
N. E. Gilhus (1995)
10.1097/JTO.0b013e3182904bc2
Distinguishing Benign Thymic Lesions from Early-Stage Thymic Malignancies on Computed Tomography
A. McErlean (2013)
10.1016/S0002-9610(99)80107-X
Hepatic resection for metastatic neuroendocrine carcinomas.
F. Que (1995)
10.1067/MTC.2002.119886
Bronchial carcinoid tumors: surgical management and long-term outcome.
P. Filosso (2002)
10.1097/00000478-199812000-00004
Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
T. Kuo (1998)
10.1016/0167-8140(94)01493-M
Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer.
D. Cowen (1995)
10.1097/JTO.0b013e3181b9eb85
Hemithoracic Radiotherapy After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Dosimetric Comparison of Two Well-Described Techniques
C. Hill-Kayser (2009)
10.1002/cncr.23097
Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA‐87 and LALA‐94 trials
Emmanuelle Tavernier (2007)
10.1097/JTO.0b013e31821c4203
Computed Tomography Findings Predicting Invasiveness of Thymoma
E. Marom (2011)
10.1002/(SICI)1096-9098(199609)63:1<17::AID-JSO4>3.0.CO;2-T
Preoperative radiotherapy and surgery for advanced thymoma with invasion to the great vessels.
E. Akaogi (1996)
10.1067/MTC.2002.125817
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
10.1042/bst0190180
Autoimmunity to acetylcholine receptors in myasthenia gravis.
A. Vincent (1991)
10.1053/HUPA.2001.28245
Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors.
Y. C. Cai (2001)
10.1002/PPUL.10249
Pediatric pulmonary carcinoid: a case report and review of the literature.
T. Moraes (2003)
10.1016/S1010-7940(02)00665-6
Recurrence of stage I thymoma in sternum, 13 years after "complete" excision.
R. Reddy (2003)
10.1378/chest.103.4_Supplement.382S
Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.
V. Rusch (1993)
10.1111/j.1600-0404.1989.tb03866.x
Increased incidence of thymoma in Chinese myasthenia gravis: possible relationship with Epstein‐Barr virus
R. Teoh (1989)
10.1148/radiology.156.1.3923554
Malignant thymoma: role of radiation therapy in management.
C. Kersh (1985)
10.1210/jcem.82.5.3944
Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1.
Q. Dong (1997)
10.1016/S0954-6111(89)80201-X
Typical and atypical bronchial carcinoids.
M. Torre (1989)
10.1007/BF01791148
Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: A preliminary report
R. Liu (2005)
10.1148/rg.302095131
Clinical and radiologic review of the normal and abnormal thymus: pearls and pitfalls.
F. Nasseri (2010)
10.1016/j.athoracsur.2012.03.004
The role of adjuvant radiation therapy for resected stage III thymoma: a population-based study.
B. Weksler (2012)
10.1148/radiology.142.1.7053522
Computed tomography of the abnormal thymus.
R. Baron (1982)
10.1038/sj.bjc.6690773
Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience
A. Berruti (1999)
10.1002/cncr.25851
Adjuvant radiotherapy for completely resected stage 2 thymoma
A. Berman (2011)
10.1053/CTRV.1999.0159
Malignant thymoma: current status and future directions.
P. Lara (2000)
10.1148/RADIOGRAPHICS.19.3.G99MA11707
Thoracic carcinoids: radiologic-pathologic correlation.
M. L. Rosado de Christenson (1999)
10.1016/S1470-2045(05)70471-X
Survival from rare cancer in adults: a population-based study.
G. Gatta (2006)
10.1016/S0002-9440(10)65166-8
DNA copy number losses in human neoplasms.
S. Knuutila (1999)
10.1016/J.LUNGCAN.2003.08.017
Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience.
L. Schrevens (2004)
10.1016/S0002-8703(97)70053-X
Cardiovascular complications of malignant carcinoid disease.
A. Anderson (1997)
10.1016/S0003-4975(98)00378-6
Multicenter VATS experience with mediastinal tumors.
T. L. Demmy (1998)
10.7555/JBR.27.20120060
Surgical approaches for stage I and II thymoma-associated myasthenia gravis: feasibility of complete video-assisted thoracoscopic surgery (VATS) thymectomy in comparison with trans-sternal resection
Zhicheng He (2013)
10.1016/S0003-4975(01)03607-4
Primary thymic carcinoma.
Hung-Chang Liu (2002)
10.1007/S002680020021
Treatment of Malignant Mesothelioma
M. Jaklitsch (2001)
10.1016/j.athoracsur.2008.11.022
Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis.
R. Korst (2009)
10.1097/COC.0b013e318042d566
Adjuvant Radiotherapy for Thymic Epithelial Tumor: Treatment Results and Prognostic Factors
Y. Kundel (2007)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1016/0003-4975(95)00669-C
Thymoma: a multivariate analysis of factors predicting survival.
D. Blumberg (1995)
10.1002/1097-0142(19890415)63:8<1493::AID-CNCR2820630807>3.0.CO;2-C
Chemotherapy of invasive thymoma. A retrospective study of 22 cases
N. Göldel (1989)
10.1002/ijc.11099
Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies
E. Engels (2003)
10.1097/JTO.0b013e3181f20ea2
Technical advances of radiation therapy for thymic malignancies.
D. Gomez (2010)
10.1016/0003-4975(90)90087-M
Carcinoid tumors of the thymus.
G. Economopoulos (1990)
10.1097/00004728-199105000-00015
CT findings in primary thymic carcinoma.
J. Lee (1991)
10.1378/CHEST.119.6.1647
Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature.
G. Fink (2001)
10.1002/jso.23256
Long-term survival in thymic epithelial tumors: a single-center experience from China.
S. Shen (2013)
10.1097/JTO.0b013e3181b6be57
Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas
G. Giaccone (2009)
10.1016/0360-3016(95)00079-E
Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer.
F. Mornex (1995)
10.1016/J.BRACHY.2004.11.003
A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma.
K. Rosenzweig (2005)
10.2152/JMI.59.225
The utility of FDG-PET in the diagnosis of thymic epithelial tumors.
H. Otsuka (2012)
10.1016/0360-3016(90)90126-5
The incidence of myelitis after irradiation of the cervical spinal cord.
R. Marcus (1990)
10.1097/JTO.0b013e3181f20ec4
Radiotherapy for thymic neoplasms.
C. Fuller (2010)
10.1136/thx.48.11.1135
How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party.
J. Thomas (1993)
10.1097/JTO.0b013e31820ce2c7
Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma
S. Kao (2011)
10.1002/(SICI)1097-0142(19990501)85:9<1871::AID-CNCR1>3.0.CO;2-Y
Nonsurgical management of malignant thymoma
M. Hejna (1999)
10.1002/1097-0142(197204)29:4<1075::AID-CNCR2820290457>3.0.CO;2-O
Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis. A previously unrecognized association
J. Rosai (1972)
10.1002/1097-0142(19921015)70:8<2077::AID-CNCR2820700811>3.0.CO;2-W
The distribution of epithelial membrane antigen in thymic epithelial neoplasms
I. Fukai (1992)
10.1002/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO;2-D
Thymoma. A clinicopathologic review
J. Lewis (1987)
10.1378/CHEST.112.4_SUPPLEMENT.296S
Controversies in the management of malignant thymoma.
L. Kohman (1997)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/0167-8140(91)90078-U
Post-operative radiotherapy in invasive thymoma.
M. Jackson (1991)
10.1002/(SICI)1097-0029(19970901)38:5<468::AID-JEMT2>3.0.CO;2-E
Typical and atypical lung carcinoids: clinical and morphological diagnosis.
C. Mendonça (1997)
10.1016/0003-4975(94)00630-P
Carcinoid tumors of the lung: do atypical features require aggressive management?
C. Marty-Ané (1995)
10.1038/bjc.1996.157
PET imaging of primary mediastinal tumours.
K. Kubota (1996)
10.1016/0960-0760(90)90469-2
Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog
S. J. Lamberts (1990)
10.1016/J.IJROBP.2004.05.013
Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients.
G. Zhu (2004)
10.1097/00000478-199808000-00003
Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
W. Travis (1998)
10.1002/(SICI)1096-9098(199902)70:2<95::AID-JSO6>3.0.CO;2-8
Primary tumors of the mediastinum.
B. Whooley (1999)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1016/J.LUNGCAN.2003.09.022
Multimodal management of stages III-IVa malignant thymoma.
S. Bretti (2004)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1016/j.ctrv.2012.11.005
Thymoma and thymic carcinoma in the target therapies era.
A. Lamarca (2013)
10.1097/JTO.0b013e3181653c8c
Pathologic Radioresponse of Preoperatively Irradiated Invasive Thymomas
T. Onuki (2008)
10.1016/S0022-5223(95)70029-3
Differential diagnosis of thymic carcinoma and lung carcinoma with the use of antibodies to cytokeratins.
I. Fukai (1995)
10.1002/JCA.20061
Prethymectomy plasmapheresis in myasthenia gravis.
J. Yeh (2005)
10.1016/J.EJCTS.2004.03.043
Thymic carcinoma. Clinical institutional experience with 15 patients.
S. Takeda (2004)
10.1016/j.athoracsur.2012.02.009
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.
J. Friedberg (2012)
10.1038/bjc.1982.15
Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment.
J. Peto (1982)
10.1016/0003-4975(90)90185-9
Analysis of prognostic factors and clinicopathological staging of thymoma.
E. Pescarmona (1990)
10.1016/S0003-4975(03)01194-9
Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification.
M. Mezzetti (2003)
10.1016/j.cryobiol.2013.06.008
Combination percutaneous cryotherapy and iodine-125 seed implantation for unresectable malignant thymoma: experience in 19 patients.
Z. Zhang (2013)
10.3109/02841869609109921
Radiosensitivity of mesothelioma cell lines.
A. Häkkinen (1996)
10.1016/0003-4975(92)91391-L
Adjuvant radiotherapy after complete resection of thymoma.
M. Haniuda (1992)
10.1016/S0003-4975(02)03828-6
Adjuvant radiation therapy for stage II thymoma.
A. Mangi (2002)
10.1200/JCO.2011.40.3147
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Jennifer A. Chan (2012)
10.1007/s002689900137
Progression of Metastases and Symptom Improvement from Laparotomy in Midgut Carcinoid Tumors
Charlie Makridis (1996)
10.1016/S0003-4975(02)04474-0
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
J. Friedberg (2003)
10.1097/JTO.0b013e3182835549
FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies
M. Benveniste (2013)
10.1093/annonc/mds147
Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas.
T. Mimae (2012)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1002/cncr.25367
Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomas
P. Zucali (2010)
10.1002/(SICI)1097-0339(199812)19:6<428::AID-DC5>3.0.CO;2-F
Fine‐needle aspiration of the mediastinum: A clinical, radiologic, cytologic, and histologic study of 42 cases
N. Shabb (1998)
10.1002/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4
Chemotherapy for invasive thymoma. A 13‐year experience
A. Fornasiero (1991)
10.1038/bjc.1992.200
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
O. Solheim (1992)
10.1016/S0169-5002(02)00080-6
Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark.
H. Skúladóttir (2002)
10.1016/S0002-9610(99)80210-4
Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization.
D. Diaco (1995)
10.1016/S0003-4975(10)62558-1
Recurrence of thymoma: clinicopathological features, therapy, and prognosis.
Y. Monden (1985)
10.1378/CHEST.124.1.141
A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus.
O. Tiffet (2003)
10.1016/j.athoracsur.2009.12.041
Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
B. Balduyck (2010)
10.1378/CHEST.119.4.1143
Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement.
C. Thomas (2001)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1016/0360-3016(92)90911-Z
Thymoma: treatment and prognosis.
A. Pollack (1992)
10.1016/j.lungcan.2010.01.015
Surgical treatment of bronchial carcinoid tumors: a single-center experience.
T. Machuca (2010)
10.1038/bjc.1997.561
High frequency of p53 protein expression in thymic carcinoma but not in thymoma.
N. Hino (1997)
10.1055/S-2005-837539
Carcinoid tumors of the lung and multimodal therapy.
D. Divisi (2005)
10.1016/J.IJROBP.2006.01.052
Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.
J. Chang (2006)
10.1002/(SICI)1097-0142(19981015)83:8<1495::AID-CNCR4>3.0.CO;2-O
Thymoma: prognostic factors and treatment outcomes.
S. Gripp (1998)
10.1002/1097-0142(19861115)58:10<2290::AID-CNCR2820581022>3.0.CO;2-4
Flushing in the carcinoid syndrome and plasma kallikrein
K. Lucas (1986)
10.1002/1097-0142(19940515)73:10<2491::AID-CNCR2820731007>3.0.CO;2-6
Thymoma. A retrospective study of 87 cases
H. S. Park (1994)
10.1378/CHEST.117.6.1787
Diagnosis and treatment of mediastinal tumors by thoracoscopy.
L. M. Cirino (2000)
10.1002/1097-0142(19880615)61:12<2475::AID-CNCR2820611215>3.0.CO;2-5
Association of the epstein‐barr virus with lymphoepithelioma of the thymus
I. Dimery (1988)
10.1002/(SICI)1097-0339(199707)17:1<61::AID-DC13>3.0.CO;2-8
Thymoma mimicking thyroid papillary carcinoma: Another pitfall in fine‐needle aspiration
Y. Oertel (1997)
10.1016/S0003-4975(00)02251-7
Giant bronchial carcinoid tumors: a multidisciplinary approach.
Stefan Fischer (2001)
10.1001/archinte.1974.00320200184029
The spectrum of diseases associated with thymoma. Coincidence or syndrome?
J. V. Souadjian (1974)
10.1016/j.lungcan.2008.03.013
Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
K. Yoh (2008)
10.1097/00000478-197706000-00002
Squamous cell carcinoma of the thymus. An analysis of eight cases
Y. Shimosato (1977)
10.1007/s00432-001-0319-9
Epidermal growth factor receptor expression in invasive thymoma
J. Henley (2002)
10.1016/S0022-5223(98)70273-9
Thymic carcinoma: current staging does not predict prognosis.
D. Blumberg (1998)
10.1053/j.semtcvs.2009.07.001
Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.
J. Friedberg (2009)
10.1182/BLOOD.V100.1.159
Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas.
P. Stroebel (2002)
10.2214/ajr.142.1.73
CT of primary germ-cell tumors of the mediastinum.
R. Levitt (1984)
10.1016/0003-4975(95)00983-3
Surgical treatment for invasive thymoma, especially when the superior vena cava is invaded.
K. Yagi (1996)
10.5761/ATCS.OA.10.01572
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
T. Yan (2011)
10.1097/SLA.0b013e3181dd4ec4
Thymic Neuroendocrine Tumors: A SEER Database Analysis of 160 Patients
P. Gaur (2010)
10.1016/S0936-6555(05)80540-0
Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy.
E. Low (1995)
10.1097/JTO.0b013e31827a8911
Postoperative proton therapy in the management of stage III thymoma.
N. Figura (2013)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.1016/0899-7071(94)00041-A
Squamous cell carcinoma of the thymus with paraneoplastic hypercalcemia.
J. M. Negron-Soto (1995)
10.1196/annals.1405.018
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms.
P. Stroebel (2008)
10.1136/thx.48.6.632
Percutaneous needle biopsy of the mediastinum: review of 94 procedures.
B. Morrissey (1993)
10.1016/S0022-5223(96)70265-9
Prognostic factors and long-term results after thymoma resection: a series of 307 patients.
J. Régnard (1996)
10.1148/RADIOLOGY.204.3.9280272
Invasive thymoma: treatment with postoperative radiation therapy.
D. Latz (1997)
10.1002/(SICI)1098-2264(200005)28:1<58::AID-GCC7>3.0.CO;2-2
MEN1 gene mutation analysis of high‐grade neuroendocrine lung carcinoma
L. Debelenko (2000)
10.1159/000029231
Parathyroid-Hormone-Related-Protein-Producing Thymic Carcinoma Presenting as a Giant Extrathoracic Mass
K. Suzuki (1998)
10.1002/cncr.10588
Treatment and prognosis of thymic carcinoma
K. Ogawa (2002)
10.1002/1097-0142(20000625)90:3<148::AID-CNCR3>3.0.CO;2-9
A review of cytologic findings in neuroendocrine carcinomas including carcinoid tumors with histologic correlation
S. A. Nicholson (2000)
10.1016/S1010-7940(02)00055-6
Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
P. Filosso (2002)
10.1016/S0025-6196(12)60697-1
Primary mediastinal neoplasms (other than thymoma).
O. A. Hoffman (1993)
10.1016/j.athoracsur.2012.01.014
Thymic carcinoma: outcomes after surgical resection.
I. Okereke (2012)
10.1080/00313029800169056
Thymic carcinoma: Spectrum of differentiation and histologic types
S. Suster (1998)
10.3816/CLC.2010.n.005
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
N. Katirtzoglou (2010)
10.1148/radiology.168.3.3136511
Stage III thymoma: results of postoperative radiation therapy.
J. Krueger (1988)
10.1378/chest.08-2482
Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms.
T. Khoury (2009)
10.1097/00000478-200005000-00014
CD70 expression in thymic carcinoma.
T. Hishima (2000)
10.1016/J.ATHORACSUR.2003.10.089
Bronchial carcinoid tumors: nodal status and long-term survival after resection.
G. Cardillo (2004)
10.1093/JJCO/HYD108
Platinum-based chemotherapy with or without thoracic radiation therapy in patients with unresectable thymic carcinoma.
Y. Nakamura (2000)
10.1016/S0039-6109(16)40093-9
Thymoma: factors influencing prognosis.
P. E. Bernatz (1973)
10.1016/j.athoracsur.2007.08.051
Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors.
C. Wright (2008)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
10.1016/S0002-9440(10)65653-2
Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
A. Walch (1998)
10.1016/S0003-4975(03)00819-1
Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation.
S. Singhal (2003)
10.1016/0167-8140(90)90154-O
Role of radiation therapy in locally advanced thymoma.
A. Urgesi (1990)
10.1080/028418698430421
Radioresponse of thymomas verified with histologic response.
K. Ohara (1998)
10.3109/02841869109092411
The role of interferons in the management of carcinoid tumors.
K. Oberg (1991)
10.1007/s12032-008-9100-0
Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report
X. Li (2009)
Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity.
D. Dorfman (1997)
10.1136/thx.49.4.357
Carcinoid tumours of the thymus.
D. Wang (1994)
10.1097/JTO.0b013e31829ceb50
Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma
L. Gao (2013)
10.1136/thorax.2003.009290
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112
M. Muers (2004)
10.1097/00043426-199124000-00011
Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19).
U. Kees (1991)
10.1016/S0003-4975(00)01140-1
Prognostic relevance of Masaoka and Müller-Hermelink classification in patients with thymic tumors.
D. Lardinois (2000)
10.1016/S0002-9440(10)64536-1
Recurrent genetic aberrations in thymoma and thymic carcinoma.
A. Zettl (2000)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/j.ijrobp.2007.11.011
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
E. Miles (2008)
10.1016/j.athoracsur.2009.05.019
Multimodality therapy for patients with invasive thymoma disseminated into the pleural cavity: the potential role of extrapleural pneumonectomy.
Y. Ishikawa (2009)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1309/3PDN-PMT5-EQTM-H0CD
Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases.
C. Moran (2000)
10.1016/S0140-6736(68)91528-6
Prostaglandins in amine-peptide-secreting tumours.
M. Sandler (1968)
10.1016/S1010-7940(01)01091-0
Prognostic factors in thymic epithelial neoplasms.
A. Ríos (2002)
10.1016/S1010-7940(00)00493-0
Long-term outcome after resection for bronchial carcinoid tumors.
M. Ferguson (2000)
10.1586/14737140.5.2.231
Pemetrexed–cisplatin combination in mesothelioma
M. Reck (2005)
10.1093/annonc/mdr626
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
L. Schirosi (2012)
10.1097/00000478-199202000-00006
Thymomas Presenting as Pleural Tumors: Report of Eight Cases
C. Moran (1992)
10.1007/BF00194697
Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21
Y. Hayashi (1995)
10.1016/S0003-4975(10)62751-8
Primary anterior mediastinal tumors in children and adults.
B. Mullen (1986)
10.1136/thx.39.8.617
Carcinoid tumours of the bronchus: a 33 year experience.
R. Hurt (1984)
10.1016/J.JTCVS.2005.07.026
Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size.
C. Wright (2005)
10.1038/modpathol.3800534
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
H. Yaziji (2006)
10.1067/MTC.2002.124389
Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors.
M. Tomita (2002)
10.1002/1097-0142(197801)41:1<117::AID-CNCR2820410118>3.0.CO;2-V
Radiation therapy control of nine patients with malignant thymoma
R. Marks (1978)
10.1002/1097-0142(197601)37:1<229::AID-CNCR2820370133>3.0.CO;2-2
Thymoma. A clinical and pathological study of 65 cases
W. Salyer (1976)
10.1002/1097-0142(19930101)71:1<99::AID-CNCR2820710116>3.0.CO;2-6
Cytokeratins in normal thymus and thymic epithelial tumors
I. Fukai (1993)
10.1002/cncr.10373
Postoperative radiotherapy for patients with completely resected thymoma
K. Ogawa (2002)
10.1002/cncr.24618
Postoperative radiation therapy after complete resection of thymoma has little impact on survival
T. Utsumi (2009)
10.1002/(SICI)1097-0142(20000401)88:7<1590::AID-CNCR13>3.0.CO;2-C
Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity
K. Laitinen (2000)
10.1002/ijc.10255
Histologic classification of thymic epithelial tumors: Comparison of established classification schemes
R. Rieker (2002)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar